Ranbezolid

Drug Profile

Ranbezolid

Alternative Names: Ranbezolid hydrochloride; RBx 7644

Latest Information Update: 30 Mar 2015

Price : $50

At a glance

  • Originator Ranbaxy Laboratories
  • Developer Sun Pharmaceutical Industries
  • Class Acetamides; Antibacterials; Furans; Oxazolidinones; Piperazines; Small molecules
  • Mechanism of Action Bacterial protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
  • 07 Jan 2009 Preclinical development is ongoing in India
  • 31 Dec 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial Infections antimicrobial activity section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top